Sangamo Therapeutics (NASDAQ:SGMO) Research Coverage Started at StockNews.com

by · The Cerbat Gem

StockNews.com initiated coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a report issued on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on SGMO. HC Wainwright reiterated a buy rating and set a $5.00 price objective on shares of Sangamo Therapeutics in a research report on Wednesday, May 15th. Royal Bank of Canada restated a sector perform rating and set a $2.00 price target on shares of Sangamo Therapeutics in a report on Thursday, March 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of Hold and a consensus target price of $5.67.

Check Out Our Latest Report on SGMO

Sangamo Therapeutics Stock Performance

NASDAQ SGMO opened at $0.36 on Wednesday. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.67. The stock has a market cap of $74.35 million, a price-to-earnings ratio of -0.19 and a beta of 1.35. The firm’s 50 day moving average price is $0.54 and its two-hundred day moving average price is $0.62.

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative return on equity of 182.55% and a negative net margin of 1,749.06%. The firm had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $8.51 million. During the same quarter in the previous year, the firm posted $0.12 earnings per share. On average, research analysts forecast that Sangamo Therapeutics will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Mackenzie Financial Corp lifted its stake in shares of Sangamo Therapeutics by 72.4% in the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 31,003 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its stake in shares of Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 23,650 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Sangamo Therapeutics by 103.9% in the 4th quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 92,002 shares during the last quarter. Golden State Equity Partners lifted its stake in shares of Sangamo Therapeutics by 21.0% in the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 34,960 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics in the 1st quarter valued at $331,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

(Get Free Report)

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Read More